A method of increasing the level of interleukin-1 receptor antagonist (IL-1RA) in a subject, comprising: identifying a subject in need thereof； and administering to the subject a composition that includes small cells that are greater than 2 micrometers and less than 6 micrometers in size； wherein the small cells include somatic stem cells that are (i) plurripotent or totipotent； and (i) CD349(+), CD9(+), Oct4(+), Nanog(+), Lgr5(+), CD66e(+), CD133(+), or CD34(+).一種增加在一個體中介白素-1受體拮抗物(IL-1RA)之位準的方法，其包含：辨識一有需要之個體；以及向該個體投予一包含有尺寸為大於2微米且小於6微米之小型細胞的組成物；其中該等小型細胞包括以下體幹細胞：(i)多功能性或者全能性；以及(i) CD349(+)、CD9(+)、Oct4(+)、Nanog(+)、Lgr5(+)、CD66e(+)、CD133(+)，或者CD34(+)。
